Sickle Cell
11
2
2
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
9.1%
1 terminated out of 11 trials
85.7%
-0.8% vs benchmark
9%
1 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (11)
Objective Neurocognitive Assessment of Young Children With Sickle Cell Disease by Eye-Tracking
Genotype -Phenotype Correlation of PKLR Variants With Pyruvate Kinase, 2,3-Diphosphglycerate and Adenosine Triphosphate Activities in Red Blood Cells of People With Sickle Cell Disease
Sickle Cell, Pain and Mediterranean Diet
Developing the Family Map: Looking at Communal Coping
Development of a Provider-Focused Intervention to Improve Health Outcomes in Pediatric Sickle Cell Disease
Impact of Regional Anesthesia on Inflammatory Mechanisms During Vaso-occlusive Crisis in Sickle Cell Patients
Therapeutic Anticoagulation Strategy for Acute Chest Syndrome
VO2max & HRQoL in Children With Sickle Cell Disease
Stem Cell Collection for Adult Volunteers
Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
Diastolic Dysfunction in Sickle Cell Disease During Vaso-occlusive Crisis